Thomas Stinchcombe

Positions:

Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1995

University of Virginia School of Medicine

Internal Medicine Residency

University of Michigan, Ann Arbor

Hematology/Oncology Fellowship

University of North Carolina, Chapel Hill, School of Medicine

Grants:

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

Administered By
Duke Cancer Institute
Awarded By
Advaxis Inc
Role
Principal Investigator
Start Date
End Date

A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naive advanced EGFR mutant lung cancer

Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Role
Principal Investigator
Start Date
End Date

A Single Arm Phase II Study Osimertinib in Patients with Stage 4 Non-small Cell Lung Cancer with Uncommon EGFR Mutations Thoracic Oncology Program (TOP) Protocol Number: TOP 1703

Administered By
Duke Cancer Institute
Awarded By
AstraZeneca LP
Role
Principal Investigator
Start Date
End Date

A Phase 1b/2, single-arm, open-label, multi-center study of MP0250 in combination with osimertinib in patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) pretreated with osimertinib

Administered By
Duke Cancer Institute
Awarded By
Molecular Partners AG
Role
Principal Investigator
Start Date
End Date

A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-line Treatment of Patients with Small Cell Lung Cancer

Administered By
Duke Cancer Institute
Awarded By
TESARO
Role
Principal Investigator
Start Date
End Date

Publications:

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

INTRODUCTION: Retrospective studies have evaluated the approach of stereotactic radiotherapy (SRT) to address oligoprogression in patients with EGFR mutant NSCLC on TKI therapy, it has never been prospectively studied. MATERIALS AND METHODS: We treated 25 patients with EGFR mutant NSCLC on erlotinib who had 3 or fewer sites of extra-cranial progression with SRT to progressing sites, followed by re-initiation of erlotinib. RESULTS: Median PFS from the initiation of SRT was 6 months (95% CI 2.5 to 11.6) and median OS was 29 months (95% CI 21.7 to 36.3). Neither baseline nor changes in the Veristrat proteomic predicted PFS. CONCLUSIONS: SRT and TKI continuation may be considered for select patients with EGFR mutant NSCLC and oligo-progression on EGFR TKI therapy.
Authors
Weiss, J; Kavanagh, B; Deal, A; Villaruz, L; Stevenson, J; Camidge, R; Borghaei, H; West, J; Kirpalani, P; Morris, D; Lee, C; Pecot, CV; Zagar, T; Stinchcombe, T; Pennell, N
MLA Citation
Weiss, Jared, et al. “Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.Cancer Treat Res Commun, vol. 19, 2019, p. 100126. Pubmed, doi:10.1016/j.ctarc.2019.100126.
URI
https://scholars.duke.edu/individual/pub1373701
PMID
30852467
Source
pubmed
Published In
Cancer Treatment and Research Communications
Volume
19
Published Date
Start Page
100126
DOI
10.1016/j.ctarc.2019.100126